- Home
- DXCM vs INSM Comparison
DXCM vs INSM Comparison
Compare DXCM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- INSM
- Stock Information
- Founded
- DXCM 1999
- INSM 1988
- Country
- DXCM United States
- INSM United States
- Employees
- DXCM N/A
- INSM N/A
- Industry
- DXCM Medical/Dental Instruments
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- DXCM Health Care
- INSM Health Care
- Exchange
- DXCM Nasdaq
- INSM Nasdaq
- Market Cap
- DXCM 31.7B
- INSM 26.0B
- IPO Year
- DXCM 2005
- INSM 2000
- Fundamental
- Price
- DXCM $76.44
- INSM $144.78
- Analyst Decision
- DXCM Strong Buy
- INSM Strong Buy
- Analyst Count
- DXCM 19
- INSM 19
- Target Price
- DXCM $99.89
- INSM $146.81
- AVG Volume (30 Days)
- DXCM 4.5M
- INSM 2.1M
- Earning Date
- DXCM 10-23-2025
- INSM 10-30-2025
- Dividend Yield
- DXCM N/A
- INSM N/A
- EPS Growth
- DXCM N/A
- INSM N/A
- EPS
- DXCM 1.43
- INSM N/A
- Revenue
- DXCM $4,300,800,000.00
- INSM $398,105,000.00
- Revenue This Year
- DXCM $17.03
- INSM $31.95
- Revenue Next Year
- DXCM $15.59
- INSM $125.46
- P/E Ratio
- DXCM $53.42
- INSM N/A
- Revenue Growth
- DXCM 9.30
- INSM 21.15
- 52 Week Low
- DXCM $57.52
- INSM $60.40
- 52 Week High
- DXCM $93.25
- INSM $149.08
- Technical
- Relative Strength Index (RSI)
- DXCM 44.18
- INSM 71.07
- Support Level
- DXCM $75.39
- INSM $138.73
- Resistance Level
- DXCM $78.96
- INSM $148.22
- Average True Range (ATR)
- DXCM 2.36
- INSM 3.85
- MACD
- DXCM 0.01
- INSM -0.92
- Stochastic Oscillator
- DXCM 36.35
- INSM 71.10
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.